Novopyxis
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1 Broadway Ste 14, Cambridge, Massachuse...Phone Number
(617) 285-9473Website
www.novopyxis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Novopyxis
Novopyxis is a biotechnology company that leverages mathematics and physics principles to innovate in drug design and delivery. Their flagship drug, NP-6A, targets the Angiotensin II Type 2 Receptor (AT2R) and is designed to address challenges in cardiomyopathy treatment. Additionally, they have developed Droplette, a patent-pending transdermal delivery system that allows for painless and effective drug delivery of larger molecules. The company collaborates with various organizations, including NASA and Brigham and Women's Hospital, to enhance their technology and research efforts.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Novopyxis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Novopyxis, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Novopyxis had a recent Job posting/layoffs
Product Launch: Get notified when Novopyxis launches new products
Earning: See what the market has to say on Novopyxis recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Novopyxis has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Novopyxis has new funding data
Congratulate Masked Content for being promoted to Masked Content at Novopyxis
Check out if Novopyxis is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Novopyxis as Masked Content
Find more new buyers
Compare Similar Companies to Novopyxis
Compare insights from companies similar to Novopyxis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Novopyxis
<$5M
1-10
Private
<$5M
2013
N/A
Company Profile Activity
Activity Insights
Novopyxis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Novopyxis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Novopyxis.
Novopyxis financials insights
Gather financial insights about Novopyxis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$512K
Novopyxis Tech Stack
A closer look at the technologies used by Novopyxis
See more technologies
Novopyxis News & Media
Amgen And LabCentral Open Nomination Process For Lab Residency
An Opportunity for Start-Ups to be Awarded a Golden Ticket CAMBRIDGE, Mass., Sept. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies. LabCentral is an innovative, shared laboratory space designed as a launchpad for premier high-impact life sciences and biotech startups. As one of LabCentral's platinum sAmgen And LabCentral Open Nomination Process For Lab Residency
CAMBRIDGE, Mass., Sept. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies. LabCentral is an...Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral
Amgen Golden Tickets Provide Innovative Startup Companies With Free Lab Space to Aid in Further Advancement of Their Science CAMBRIDGE, Mass., Dec. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge R&D andAmgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral
Amgen Golden Tickets Provide Innovative Startup Companies With Free Lab Space to Aid in Further Advancement of Their Science CAMBRIDGE, Mass., Dec. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge R&D and
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Novopyxis
Sign Up For FreeTo access detailed company insights
Novopyxis is a biotechnology company that leverages mathematics and physics principles to innovate in drug design and delivery. Their flagship drug, NP-6A, targets the Angiotensin II Type 2 Receptor (AT2R) and is designed to address challenges in cardiomyopathy treatment. Additionally, they have developed Droplette, a patent-pending transdermal del... Read More
